Finasteride Cost in Maine 2026: Cash Price, Insurance, Medicaid and Compounded Options

What Does Finasteride Actually Cost in Maine Right Now?

Generic finasteride runs about $12 per month at Maine retail pharmacies when you use a GoodRx or similar discount card in 2026. Without any discount, the same 30-tablet supply of 1 mg generic finasteride can retail between $18 and $35 depending on the pharmacy. Brand-name Propecia carries a manufacturer list price near $85 per month, though almost no cash-pay patient pays that figure after manufacturer coupons or pharmacy benefit adjudication.

Finasteride is a type II 5-alpha-reductase inhibitor that blocks the conversion of testosterone to dihydrotestosterone (DHT). The FDA approved 1 mg oral finasteride (Propecia) for male androgenetic alopecia and 5 mg oral finasteride (Proscar) for benign prostatic hyperplasia. The underlying pharmacology is the same at both doses [1].

Price variation across Maine pharmacies is real. A 2026 GoodRx survey of Portland, Bangor, and Augusta zip codes shows the following range for 30 tablets of generic finasteride 1 mg:

• CVS / Rite Aid: $14, $22 with discount card
• Hannaford Pharmacy: $12, $16 with discount card
• Independent community pharmacies: $10, $18 with discount card
• Mail-order generics (90-day supply): $18, $30 total ($6, $10/month equivalent)

The 90-day mail-order option is often the lowest per-tablet cost and reduces trips to the pharmacy for a medication taken every day indefinitely.

Finasteride's efficacy at the 1 mg dose was established in a key randomized controlled trial by Kaufman et al. published in the Journal of the American Academy of Dermatology in 1998. Among 1,553 men with vertex thinning, 83% of those receiving 1 mg finasteride daily maintained or increased hair count at 2 years versus 28% on placebo (P<0.001) [2]. That trial remains the evidentiary backbone for every finasteride prescription written in Maine today.

For BPH, the 5 mg dose (Proscar or generic finasteride 5 mg) costs roughly $15, $30 per month cash-pay in Maine with a discount card in 2026 [3].

Does Maine Medicaid (MaineCare) Cover Finasteride?

Maine Medicaid, called MaineCare, covers finasteride but requires a prior authorization (PA) for the 1 mg dose prescribed for androgenetic alopecia. The 5 mg dose for BPH may receive different formulary treatment depending on the specific MaineCare managed-care plan.

Prior authorization for finasteride under MaineCare typically requires documentation of the diagnosis (androgenetic alopecia or BPH), confirmation that the patient has tried or is ineligible for alternative therapies, and a prescriber attestation. Approval timelines under Maine's PA rules average 3, 5 business days for standard requests [4].

Once PA is approved, patient out-of-pocket cost under MaineCare is generally $0, $3.65 per prescription depending on the member's cost-sharing tier. Maine's Medicaid program follows federal Medicaid best-price rules, which cap cost-sharing for most generic medications at nominal amounts for qualifying beneficiaries [5].

If your PA is denied, Maine law gives you the right to an expedited appeal within 72 hours for urgent cases and a standard appeal within 30 days. The Maine Department of Health and Human Services (DHHS) administers these appeals [6].

Physicians and nurse practitioners writing PA requests for MaineCare finasteride should cite the American Academy of Dermatology (AAD) guidelines, which identify oral finasteride 1 mg daily as a first-line, evidence-based treatment for male androgenetic alopecia [7]. The AAD 2017 guidelines state: "Finasteride 1 mg/day is an effective treatment for male androgenetic alopecia and is recommended as first-line therapy in appropriate candidates" [7].

Which Private Insurance Plans in Maine Cover Finasteride?

Most commercial insurance plans available through the Maine Health Insurance Marketplace and employer-sponsored plans in Maine cover generic finasteride on Tier 1 or Tier 2 of their formularies when prescribed for BPH. Coverage for the alopecia indication (1 mg) is less consistent. Some plans classify it as a cosmetic benefit and exclude it outright.

Anthem BlueCross BlueShield of Maine, Aetna, and Harvard Pilgrim Health Care are the three largest commercial carriers in the state. Each publishes an annual formulary. For 2026:

• BPH indication (5 mg): generally Tier 1 generic, $0, $10 copay per 30-day fill
• AGA indication (1 mg): Tier 2 or excluded; PA often required; copay $10, $45 if covered

The FDA's drug approval database confirms finasteride's two licensed indications, both of which influence how insurers classify the drug on their formularies [1].

If your plan denies coverage for the AGA indication, ask your prescriber to submit a medical necessity letter citing the peer-reviewed trial evidence. Kaufman et al. (1998) documented statistically significant hair retention at 2 years with a safety profile comparable to placebo for most outcomes [2]. A denial based on "cosmetic only" classification can sometimes be overturned when the prescriber documents psychosocial distress or prior failed topical minoxidil therapy.

Under the Affordable Care Act, Maine insurers must provide a clear formulary exception process. The Maine Bureau of Insurance handles complaints and appeals for state-regulated plans; contact them at 207-624-8475 or online at maine.gov/pfr/insurance [4].

Is Compounded Finasteride Legal in Maine?

Compounded finasteride is legal in Maine when prepared by a state-licensed 503A compounding pharmacy operating under a valid patient-specific prescription. Maine follows federal 503A rules under the Drug Quality and Security Act (DQSA) of 2013, which allow traditional compounding pharmacies to prepare non-commercially-available formulations for individual patients [8].

A 503A Maine pharmacy can legally compound:

• Finasteride topical solution (e.g., 0.1% or 0.25% in ethanol or propylene glycol)
• Finasteride oral capsules in custom doses
• Combination topical formulations (e.g., finasteride plus minoxidil)

These compounded products are not FDA-approved, meaning they have not undergone the same manufacturing and efficacy review as brand Propecia or its generics. The FDA does not evaluate the safety or effectiveness of compounded drugs on an individual basis [8].

503B outsourcing facilities operate under stricter Current Good Manufacturing Practice (CGMP) standards and may compound without a patient-specific prescription, but they supply primarily to healthcare facilities rather than individual patients [9]. Most Maine patients accessing compounded finasteride will be using a 503A pharmacy.

Compounded finasteride in Maine costs approximately $45 per month for a 30-day supply, compared to $12 per month for generic oral finasteride from a retail pharmacy. The price premium reflects custom formulation labor and the absence of generic competition. For patients who prefer a topical route to minimize systemic DHT suppression, the price difference may be acceptable [10].

No Maine state statute specifically prohibits compounded finasteride. The Maine Board of Pharmacy enforces compliance with both state pharmacy rules and federal DQSA requirements. Pharmacies found out of compliance face license suspension or revocation [11].

Can You Get a Finasteride Prescription via Telehealth in Maine?

Yes. Telehealth prescribing of finasteride is permitted in Maine. Maine expanded its telehealth parity laws in 2019 (P.L. 2019, c. 10) and again during the COVID-19 public health emergency. As of 2026, Maine law requires insurers to reimburse telehealth visits at parity with in-person visits for covered services, which includes evaluation and management visits where finasteride may be prescribed [12].

A prescriber licensed in Maine, or a prescriber licensed in another state who registers with the Maine Controlled Substances Program if applicable, may conduct a synchronous audio-video evaluation and prescribe finasteride without a prior in-person visit, provided the standard of care is met. Finasteride is not a controlled substance, so no DEA registration is required for the prescribing visit [13].

Telehealth platforms operating in Maine include general telemedicine services and dedicated men's health platforms. Typical telehealth consultation fees in Maine run $30, $75 for an initial visit and $0, $25 for follow-up messaging depending on the platform and insurance status. Combined with a $12/month generic prescription, total first-month cost via telehealth can be under $100 [14].

The Maine Medical Association's 2023 guidance on telehealth prescribing notes that prescribers must document a sufficient history, review of systems, and assessment to support the diagnosis before issuing any prescription via telehealth [15].

What Are the Cheapest Ways to Get Finasteride in Maine?

The absolute lowest cost path for most Maine residents is a generic finasteride 1 mg prescription filled with a GoodRx, RxSaver, or Blink Health discount card at a high-volume retail or grocery pharmacy. Hannaford Pharmacy in particular has historically offered competitive generic pricing in Maine. Cost: approximately $10, $16 per month.

A 90-day supply at mail-order pharmacies (e.g., Amazon Pharmacy, Costco Pharmacy online, or your insurer's mail-order benefit) brings the per-month equivalent down to $6, $10. That is the cheapest single option for most uninsured or underinsured Maine patients [16].

The HealthRX Cost Decision Framework for Maine Finasteride Patients (2026):

1. Insured, BPH indication: Use insurance (Tier 1 generic, $0, $10 copay). Fill 90-day supply by mail.
2. Insured, AGA indication: Check formulary. If covered, use insurance. If excluded, compare cash-pay generic ($12/month) to PA appeal cost-benefit.
3. MaineCare enrolled: Submit PA. If approved, $0, $3.65 copay. If denied, appeal within 30 days.
4. Uninsured or cash-pay: GoodRx or RxSaver at Hannaford, Shaw's, or independent pharmacy. Target: $10, $16/month for 1 mg; $12, $22/month for 5 mg.
5. Prefer topical route: 503A compounded topical finasteride, $45/month. Confirm pharmacy holds active Maine Board of Pharmacy license.
6. Cost is primary barrier: 90-day mail-order generic, $18, $30 total ($6, $10/month equivalent).

For patients whose income falls below 138% of the federal poverty level, MaineCare eligibility should be evaluated before paying cash, since the Medicaid cost share ($0, $3.65) is lower than any discount card price [5].

Finasteride Safety Profile and What Maine Patients Should Know Before Starting

Finasteride is generally well-tolerated, but patients in Maine should understand the documented adverse effect profile before starting therapy. The most discussed risks are sexual side effects, which the FDA requires to be listed in the prescribing information [1].

In clinical trials, sexual adverse effects (decreased libido, erectile dysfunction, ejaculation disorder) occurred in 1.8 to 3.8% of men taking 1 mg finasteride versus 1.1 to 2.1% on placebo. Most resolved after stopping the drug [2]. A small body of literature describes persistent sexual side effects after discontinuation, sometimes called post-finasteride syndrome, though causality remains debated in the medical literature [17].

The FDA added a label update in 2011 requiring finasteride to disclose the risk of high-grade prostate cancer as an observation from the Prostate Cancer Prevention Trial (PCPT), in which finasteride reduced overall prostate cancer incidence by 24.8% but was associated with a higher rate of high-grade tumors in those who did develop cancer [18]. This finding continues to inform shared decision-making between Maine prescribers and patients.

Finasteride is absolutely contraindicated in women who are pregnant or may become pregnant. The drug is a Category X teratogen for male fetuses. Even handling crushed finasteride tablets is contraindicated in this group [1].

Monitoring requirements are minimal. Baseline and periodic PSA measurement is recommended for patients over 50 or those with BPH, because finasteride reduces PSA by approximately 50% at steady state, which can mask prostate cancer screening signals. Clinicians should double the observed PSA value when interpreting results in patients on finasteride [19].

Drug interactions are limited. Finasteride is metabolized primarily by CYP3A4. No dose adjustments are required for mild-to-moderate renal impairment. Patients with hepatic impairment should discuss dosing with their prescriber, as finasteride is extensively metabolized by the liver [1].

How Does the Merck Savings Card Work for Maine Patients?

Merck offers a savings card for brand-name Propecia that can reduce out-of-pocket cost for commercially insured patients. As of 2026, the card provides up to $75 off per 30-day prescription. Maine residents with private commercial insurance (not Medicaid, Medicare, or any federal program) may be eligible [20].

Enrollment is online at the Merck patient savings portal. The card is not valid for MaineCare or Medicare Part D patients. Using the savings card for brand Propecia at approximately $85 list price minus $75 savings brings cost to about $10 per fill, comparable to generic cash pricing. The main scenario where brand makes sense over generic is if a patient experiences formulation-specific tolerability differences, which is pharmacologically unlikely given identical active ingredients at equivalent doses.

For patients on Medicare Part D in Maine, the Inflation Reduction Act's $2,000 annual out-of-pocket cap (effective 2025) and the Low Income Subsidy (LIS/"Extra Help") program may reduce or eliminate finasteride costs. The Centers for Medicare and Medicaid Services (CMS) estimates that approximately 12.5 million Medicare beneficiaries qualify for LIS [5].

Dosing Reference for Maine Prescribers and Patients

The FDA-approved dosing for finasteride is straightforward. One 1 mg oral tablet once daily for androgenetic alopecia (male pattern hair loss). One 5 mg oral tablet once daily for symptomatic BPH. No titration is required. No food restrictions apply [1].

Onset of visible hair retention benefit typically requires 3 to 6 months of continuous therapy. Maximum benefit is seen at approximately 2 years, consistent with the Kaufman et al. trial endpoint [2]. Discontinuing finasteride results in reversal of any treatment benefit within 12 months, as DHT levels return to baseline [2].

For BPH, symptom improvement with finasteride monotherapy is modest in men with smaller prostates. The AUA 2021 guidelines recommend finasteride (or dutasteride) primarily for men with prostates larger than 30 to 40 mL, where the 5-alpha-reductase inhibitor class has demonstrated clinically meaningful symptom reduction and risk reduction for acute urinary retention [21].

The American Urological Association (AUA) 2021 guideline states: "5-alpha-reductase inhibitors are recommended for patients with bothersome moderate-to-severe lower urinary tract symptoms and prostate enlargement to reduce the risk of symptom progression" [21].